The global Next Generation Cancer Diagnostics Marketstudy analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Technology (Next-generation Sequencing, qPCR & Multiplexing, Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays), By Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis), By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others), By Function, Therapeutic Monitoring, Companion Diagnostics, Prognostics, Cancer Screening, Risk Analysis).
The Next Generation Cancer Diagnostics market demonstrates remarkable growth in 2024, propelled by the increasing incidence of cancer worldwide, the growing demand for personalized and targeted cancer therapies, and the technological advancements in genomic, proteomic, and liquid biopsy-based diagnostic technologies that enable early detection, accurate diagnosis, and treatment selection in oncology. Next-generation cancer diagnostics encompass a range of molecular and imaging-based assays, genomic profiling platforms, and liquid biopsy tests used to analyze tumor biomarkers, genetic mutations, and circulating tumor cells, facilitating precision oncology approaches and guiding therapeutic decision-making in cancer care. Market dynamics are shaped by factors such as the expanding applications of next-generation sequencing (NGS) and multiplexed PCR technologies in cancer genomics, the rising adoption of liquid biopsy assays for non-invasive tumor profiling and monitoring, and the development of integrated diagnostic platforms, artificial intelligence algorithms, and digital pathology solutions that streamline cancer diagnosis and molecular characterization. Collaboration between diagnostic companies, oncologists, and academic research institutions drives innovation in the Next Generation Cancer Diagnostics market, leading to the commercialization of novel companion diagnostics, prognostic biomarkers, and predictive molecular signatures that improve patient stratification, clinical trial enrollment, and treatment outcomes across various cancer types and disease stages.
A prominent trend in the Next Generation Cancer Diagnostics Market is the increasing integration of multi-omics approaches. As understanding of cancer biology deepens, there's a growing recognition of the complexity and heterogeneity of tumors. Multi-omics techniques, including genomics, transcriptomics, proteomics, and metabolomics, allow for comprehensive analysis of cancer at various molecular levels. Integrating these multi-omics approaches into cancer diagnostics enables more precise tumor characterization, personalized treatment selection, and improved patient outcomes, thereby shaping the market towards more advanced diagnostic platforms.
A significant driver propelling the Next Generation Cancer Diagnostics Market is the growing demand for precision medicine and targeted therapies. Conventional cancer diagnostics often provide limited information about tumor biology and treatment response, leading to suboptimal therapeutic outcomes. Next-generation cancer diagnostics offer the ability to identify specific molecular alterations, biomarkers, and therapeutic targets within individual tumors, guiding the selection of targeted therapies and personalized treatment strategies. The increasing emphasis on precision medicine drives the demand for advanced cancer diagnostic technologies, stimulating market growth.
An enticing opportunity within the Next Generation Cancer Diagnostics Market lies in expansion into liquid biopsy and early detection technologies. Liquid biopsy approaches, such as circulating tumor DNA (ctDNA) analysis, offer non-invasive methods for detecting cancer-related mutations and monitoring disease progression. Additionally, early detection technologies, including imaging modalities and biomarker assays, enable the identification of cancer at its earliest stages when treatment is most effective. By investing in the development of liquid biopsy and early detection tools, companies can address unmet needs in cancer screening, improve patient outcomes through early intervention, and capitalize on the growing demand for non-invasive diagnostic solutions, thus unlocking new opportunities for market expansion.
By Technology
Next-generation Sequencing
qPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Protein Microarrays
DNA Microarrays
By Application
Biomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
By Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Others
By Function
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Abbott
Agilent Technologies Inc
F. Hoffmann-La Roche Ltd
GE HealthCare
Illumina Inc
Janssen Pharmaceuticals Inc
Koninklijke Philips N.V.
Novartis AG
QIAGEN
Thermo Fisher Scientific Inc
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Next Generation Cancer Diagnostics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Next Generation Cancer Diagnostics Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Next Generation Cancer Diagnostics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Next Generation Cancer Diagnostics Market Size Outlook, $ Million, 2021 to 2030
3.2 Next Generation Cancer Diagnostics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Next Generation Cancer Diagnostics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Next Generation Cancer Diagnostics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Next Generation Cancer Diagnostics Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Next Generation Cancer Diagnostics Industry
4.2 Key Market Trends in Next Generation Cancer Diagnostics Industry
4.3 Potential Opportunities in Next Generation Cancer Diagnostics Industry
4.4 Key Challenges in Next Generation Cancer Diagnostics Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Next Generation Cancer Diagnostics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Next Generation Cancer Diagnostics Market Outlook by Segments
7.1 Next Generation Cancer Diagnostics Market Outlook by Segments, $ Million, 2021- 2030
By Technology
Next-generation Sequencing
qPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Protein Microarrays
DNA Microarrays
By Application
Biomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
By Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Others
By Function
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
8 North America Next Generation Cancer Diagnostics Market Analysis and Outlook To 2030
8.1 Introduction to North America Next Generation Cancer Diagnostics Markets in 2024
8.2 North America Next Generation Cancer Diagnostics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Next Generation Cancer Diagnostics Market size Outlook by Segments, 2021-2030
By Technology
Next-generation Sequencing
qPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Protein Microarrays
DNA Microarrays
By Application
Biomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
By Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Others
By Function
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
9 Europe Next Generation Cancer Diagnostics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Next Generation Cancer Diagnostics Markets in 2024
9.2 Europe Next Generation Cancer Diagnostics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Next Generation Cancer Diagnostics Market Size Outlook by Segments, 2021-2030
By Technology
Next-generation Sequencing
qPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Protein Microarrays
DNA Microarrays
By Application
Biomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
By Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Others
By Function
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
10 Asia Pacific Next Generation Cancer Diagnostics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Next Generation Cancer Diagnostics Markets in 2024
10.2 Asia Pacific Next Generation Cancer Diagnostics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Next Generation Cancer Diagnostics Market size Outlook by Segments, 2021-2030
By Technology
Next-generation Sequencing
qPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Protein Microarrays
DNA Microarrays
By Application
Biomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
By Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Others
By Function
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
11 South America Next Generation Cancer Diagnostics Market Analysis and Outlook To 2030
11.1 Introduction to South America Next Generation Cancer Diagnostics Markets in 2024
11.2 South America Next Generation Cancer Diagnostics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Next Generation Cancer Diagnostics Market size Outlook by Segments, 2021-2030
By Technology
Next-generation Sequencing
qPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Protein Microarrays
DNA Microarrays
By Application
Biomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
By Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Others
By Function
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
12 Middle East and Africa Next Generation Cancer Diagnostics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Next Generation Cancer Diagnostics Markets in 2024
12.2 Middle East and Africa Next Generation Cancer Diagnostics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Next Generation Cancer Diagnostics Market size Outlook by Segments, 2021-2030
By Technology
Next-generation Sequencing
qPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Protein Microarrays
DNA Microarrays
By Application
Biomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
By Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Others
By Function
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott
Agilent Technologies Inc
F. Hoffmann-La Roche Ltd
GE HealthCare
Illumina Inc
Janssen Pharmaceuticals Inc
Koninklijke Philips N.V.
Novartis AG
QIAGEN
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Technology
Next-generation Sequencing
qPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Protein Microarrays
DNA Microarrays
By Application
Biomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
By Cancer Type
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Others
By Function
Therapeutic Monitoring
Companion Diagnostics
Prognostics
Cancer Screening
Risk Analysis
The global Next Generation Cancer Diagnostics Market is one of the lucrative growth markets, poised to register a 10.5% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Abbott, Agilent Technologies Inc, F. Hoffmann-La Roche Ltd, GE HealthCare, Illumina Inc, Janssen Pharmaceuticals Inc, Koninklijke Philips N.V., Novartis AG, QIAGEN, Thermo Fisher Scientific Inc
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume